Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LMWH versus apixaban for venous thromboembolism prophylaxis after laparoscopic sleeve gastrectomy
PACTR202410819654281Phase 3Completed
- Sponsor
- Cairo University
- Start
- Aug 2022
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of apixaban and low molecular weight heparin calcium in venous thromboembolism (VTE) (2 arms), sponsored by Cairo University. Primary endpoints: Incidence of venous thromboembolism and Incidence of bleeding. Started Aug 2022; status: completed.
02
Drugs
apixabanlow molecular weight heparin calcium
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on PACTR202410819654281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202410819654281.